A5067310876- Neurogenetic and Muscular Disorders Research
- Muscle Physiology and Disorders
- Atrial Fibrillation Management and Outcomes
- Intracranial Aneurysms: Treatment and Complications
- Healthcare cost, quality, practices
- Mechanical Circulatory Support Devices
- Musculoskeletal Disorders and Rehabilitation
- Intracerebral and Subarachnoid Hemorrhage Research
- Inflammatory mediators and NSAID effects
- Diet and metabolism studies
- Eicosanoids and Hypertension Pharmacology
- Metabolism, Diabetes, and Cancer
- Gut microbiota and health
- Vascular Malformations Diagnosis and Treatment
- Receptor Mechanisms and Signaling
- Healthcare Policy and Management
- Amyotrophic Lateral Sclerosis Research
University of Alberta
2014-2021
Institute of Genetics
2021
University of Copenhagen
2021
Johns Hopkins University
2007-2011
We report the recruitment activities and outcomes of a multi-disease neuromuscular patient registry in Canada. The Canadian Neuromuscular Disease Registry (CNDR) registers individuals across Canada with confirmed diagnosis disease. Diagnosis contact information are collected all diseases detailed prospective data is for 5 specific diseases: Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myotonic (DM), Limb Girdle (LGMD), Spinal Atrophy (SMA). Since 2010, CNDR has...
Spinal muscular atrophy (SMA) is a devastating rare disease that affects individuals regardless of ethnicity, gender, and age. The first-approved disease-modifying therapy for SMA, nusinursen, was approved by Health Canada, as well American European regulatory agencies following positive clinical trial outcomes. trials were conducted in narrow pediatric population defined age, severity, genotype. Broad approval necessitates close follow-up potential adverse events effectiveness the larger...
Background: Recent studies suggest that prolonged cardiac monitoring may identify paroxysmal atrial fibrillation (PAF) in up to 18% of patients with cryptogenic stroke.PAF occur patient where an additional etiology account for the cause stroke .We prospectively monitored presenting a TIA or whom preliminary investigations (including Holter) did not show fibrillation. Methods: Prospective non-randomized study and acute between September 2012 2013 Spider Flash-t™ Monitors (Sorin) were attached...
Introduction: Atrial fibrillation (AF) related cardioembolic stroke accounts for over 20% of ischemic stroke. Recent reports using prolonged cardiac rhythm monitoring (PCRM) in cryptogenic reveal paroxysmal AF (PAF) an additional patients. We report our findings with PCRM patients and without whom initial 24-h Holter was negative. Methods: Patients admitted to the service no previous history on were enrolled 3 weeks PCRM. used a PAF predictive score determine risk arrhythmia. All studies...
An abstract is not available for this content. As you have access to content, full HTML content provided on page. A PDF of also in through the ‘Save PDF’ action button.
Abstract C57BL/6NTac (B6NTac) and C57BL/6NRj (B6NRj) mice were fed a high calorie diet treated with liraglutide. 42 would have been needed in an ordinary one-way ANOVA to show reduction glycosylated hemoglobin (HbA1c) B6NTac mice, but incorporating the sequenced fecal microbiota two-way reduced group size obtain statistical significance 12 mice. In B6NRj there was no impact of liraglutide on HbA1c neither or without incorporation. both sub-strains, effect glucose tolerance body weight...